Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Applied Health Economics and Health Policy
Published in: Applied Health Economics and Health Policy 3/2016

Open Access 01-06-2016 | Original Research Article

Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA

Authors: Ken O’Day, Wayne C. Levy, Meridith Johnson, Arnold F. Jacobson

Published in: Applied Health Economics and Health Policy | Issue 3/2016

Login to get access

Abstract

Background

Many guideline-eligible heart failure (HF) patients do not receive a survival benefit from implantable cardioverter defibrillators (ICDs). Improved risk stratification may help to reduce costs and improve the cost effectiveness of ICDs.

Objective

To estimate the potential outcomes, costs, and cost effectiveness of using iodine-123 meta-iodobenzylguanidine (I-mIBG) to screen HF patients eligible for an ICD.

Methods

A decision-analytic model was developed to compare screening with I-mIBG imaging and no screening over 2-year and 10-year time horizons from a US payer perspective. Data on I-mIBG imaging and risk stratification were obtained from the ADMIRE-HF/HFX (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) trial. Data on ICD effectiveness for prevention of sudden cardiac death (SCD) were obtained from a meta-analysis. Costs of ICDs and costs of generator and lead procedures were obtained from the Agency for Healthcare Research and Quality National Inpatient Sample. Age-specific mortality was modeled using US life tables and data from the ACT (Advancements in ICD Therapy) Registry on risks of SCD and non-SCD mortality. Sensitivity analyses were conducted.

Results

In the analysis, screening with I-mIBG imaging was associated with a reduction in ICD utilization of 21 %, resulting in a number needed to screen to prevent 1 ICD implantation of 5. Screening reduced the costs per patient by US$5500 and US$13,431 (in 2013 dollars) over 2 and 10 years, respectively, in comparison with no screening and resulted in losses of 0.001 and 0.040 life-years, respectively, over 2 and 10 years. Screening was decrementally cost effective, with savings of US$5,248,404 and US$513,036 per quality-adjusted life-year lost over 2 and 10 years, respectively. In subgroup analyses, cost savings were greater for patients with an ejection fraction (EF) of 25–35 % than for those with an EF <25 %.

Conclusions

According to the model, screening of guideline-eligible patients selected for ICDs with I-mIBG imaging may be cost effective and may help reduce costs associated with implantation of ICDs, with a minimal impact on survival.
Appendix
Available only for authorised users
Literature
1.
Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104:2158–63.CrossRefPubMed
2.
3.
Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary. J Am Coll Cardiol. 2008;51:2085–105.CrossRef
4.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML, Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New Engl J Med. 2002;346:877–83.CrossRefPubMed
5.
Bardy GH, Lee KL, Mark DB, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New Engl J Med. 2005;352:225–37.CrossRefPubMed
6.
Kadish A, Schaechter A, Subacius H, Thattassery E, Sanders W, Anderson KP, Dyer A, Goldberger J, Levine J. Patients with recently diagnosed nonischemic cardiomyopathy benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006;47:2477–82.CrossRefPubMed
7.
Gialama F, Prezerakos P, Maniadakis N. The cost effectiveness of implantable cardioverter defibrillators: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2014;12:41–9.CrossRefPubMed
8.
Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, McNitt S, Andrews ML, MADIT II Investigators. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288–96.CrossRefPubMed
9.
Lorvidhaya P, Addo K, Chodosh A, Iyer V, Lum J, Buxton AE. Sudden cardiac death risk stratification in patients with heart failure. Heart Fail Clin. 2011;7(2):157–74, vii.
10.
van Rees JB, Borleffs CJ, van Welsenes GH, et al. Clinical prediction model for death prior to appropriate therapy in primary prevention implantable cardioverter defibrillator patients with ischaemic heart disease: the FADES Risk Score. Heart. 2012;98:872–7.CrossRefPubMed
11.
Jacobson AF, Senior R, Cerqueira MD, ADMIRE-HF Investigators, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure: results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study. J Am Coll Cardiol. 2010;55:2212–21.CrossRefPubMed
12.
Ketchum ES, Jacobson AF, Caldwell JH, et al. Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol. 2012;19:1007–16.CrossRefPubMed
13.
Jain JK, Hauptman PJ, Spertus JA, et al. Incremental utility of iodine-123 meta-iodobenzylguanidine imaging beyond established heart failure risk models. J Cardiac Fail. 2014;20:577–83.CrossRef
14.
15.
Narula J, Gerson M, Thomas GS, Cerqueira MD, Jacobson AF. I-MIBG imaging for prediction of mortality and potentially fatal events in heart failure: the ADMIRE-HFX study. J Nucl Med. 2015;56:1011–8.CrossRefPubMed
16.
Gasparini M, Menozzi C, Proclemer A, et al. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT study. Eur Heart J. 2009;30:2758–67.CrossRefPubMedPubMedCentral
17.
Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis. Europace. 2010;12:1564–70.CrossRefPubMedPubMedCentral
18.
Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. J Am Coll Cardiol. 2011;58:1007–13.CrossRefPubMed
19.
Arias E. United States life tables, 2008. National vital statistics reports, vol. 61(3). Hyattsville: National Center for Health Statistics; 2012.
20.
Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2009. National vital statistics reports. Vol 60(4). Hyattsville: National Center for Health Statistics; 2012.
21.
Epstein AE, Kay GN, Plumb VJ, ACT Investigators, et al. Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm. 2009;6:1136–43.CrossRefPubMed
22.
23.
Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. New Engl J Med. 2005;353:1471–80.CrossRefPubMed
24.
Rordorf R, Poggio L, Savastano S, et al. Failure of implantable cardioverter-defibrillator leads: a matter of lead size? Heart Rhythm. 2013;10:184–90.CrossRefPubMed
25.
Wilkoff BL, Auricchio A, Brugada J, Heart Rhythm Society (HRS), European Heart Rhythm Association (EHRA), American College of Cardiology (ACC), American Heart Association (AHA), European Society of Cardiology (ESC), Heart Failure Association of ESC (HFA), Heart Failure Society of America (HFSA), et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Europace. 2008;10:707–25.CrossRefPubMed
26.
Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibrillator shocks in patients with heart failure. New Engl J Med. 2008;359:1009–17.CrossRefPubMedPubMedCentral
27.
28.
Li Y, Levy WC, Neilson MP, et al. Associations between Seattle Heart Failure Model scores and medical resource use and costs: findings from HF-ACTION. J Cardiac Fail. 2014;20:541–7.CrossRef
29.
Unroe KT, Greiner MA, Hernandez AF, Whellan DJ, Kaul P, Schulman KA, Peterson ED, Curtis LH. Resource use in the last 6 months of life among Medicare beneficiaries with heart failure, 2000–2007. Arch Intern Med. 2011;171:196–203.CrossRefPubMed
30.
Li Y, Neilson MP, Whellan DJ, Schulman KA, Levy WC, Reed SD. Associations between Seattle Heart Failure Model scores and health utilities: findings from HF-ACTION. J Cardiac Fail. 2013;19:311–6.CrossRef
31.
Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, Martin PA. The Beaver Dam Health Outcomes Study: initial catalog of health state quality factors. Med Decis Making. 1993;13:89–102.CrossRefPubMed
32.
Nelson AL, Cohen JT, Greenberg D, Kent DM. Much cheaper, almost as good: decrementally cost-effective medical innovation. Ann Intern Med. 2009;151(9):662–7.CrossRefPubMed
33.
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245.CrossRefPubMed
34.
Mehra MR, Albert NM, Curtis AB, Gheorghiade M, Heywood JT, Liu Y, O’Connor CM, Reynolds D, Walsh MN, Yancy CW, Fonarow GC. Factors associated with improvement in guideline-based use of ICDs in eligible heart failure patients. Pacing Clin Electrophysiol. 2012;35:135–45.CrossRefPubMed
35.
Pedretti RFE, Curnis A, Massa R, et al. Proportion of patients needing an implantable cardioverter defibrillator on the basis of current guidelines: impact on healthcare resources in Italy and the USA. Data from the ALPHA study registry. Europace. 2010;12:1105–11.CrossRefPubMed
36.
Al-Khatib SM, Hellkamp AS, Fonarow GC, et al. Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30 % and 35 %. J Am Med Assoc. 2014;311(21):2209–15.CrossRef
37.
Kini V, Soufi MK, Deo R, Epstein AE, Bala R, Riley M, Groeneveld PW, Shalaby A, Dixit S. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol. 2014;63(22):2388–94.CrossRefPubMed
38.
Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studies of 123i-mibg imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. J Am Coll Cardiol Img. 2013;6:772–84.CrossRef
Metadata
Title
Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA
Authors
Ken O’Day
Wayne C. Levy
Meridith Johnson
Arnold F. Jacobson
Publication date
01-06-2016
Publisher
Springer International Publishing
Published in
Applied Health Economics and Health Policy / Issue 3/2016
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-016-0234-5

Other articles of this Issue 3/2016

Applied Health Economics and Health Policy 3/2016 Go to the issue

Original Research Article

Cost Implications for Subsequent Perinatal Outcomes After IVF Stratified by Number of Embryos Transferred: A Five Year Analysis of Vermont Data

Original Research Article

Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making

Original Research Article

The Role of Physician Recommendations and Public Policy in Human Papillomavirus Vaccinations

Original Research Article

Using Phase-Based Costing of Real-World Data to Inform Decision–Analytic Models for Atrial Fibrillation

Original Research Article

Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand

Review Article

The TURis System for Transurethral Resection of the Prostate: A NICE Medical Technology Guidance